latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/44855005 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE

Login to Market Intelligence Platform

New User / Forgot Password


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Biotechs grapple with risks as Right To Try becomes a reality

5-Year Virtual Multichannel Revenue Forecast Underscores Segment's Opportunities

Wake Up Savers, Watch Out Banks - CDs Back In Vogue - Episode 25

Financial Consumer Watchdog's Powerful Investigative Tool Faces Overhaul - Episode 26

SNL Banker


Biotechs grapple with risks as Right To Try becomes a reality

A week after President Donald Trump signed the right-to-try bill into law, biotechnology companies are staking out their positions amid looming pressure.

The Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right To Try Act, or S.204, signed May 30 by the president, opens the door for terminally ill patients to request access to experimental, early-stage therapies outside the realm of clinical trials.

For supporters, it gives dying patients hope and the possibility of life-changing treatment; for detractors, it puts pressure on drugmakers to supply untested treatments in uncertain circumstances.

On the sidelines of the annual BIO International Convention in Boston, company executives discussed the path forward as the law becomes a reality.

"We would never use this new pathway," Alnylam Pharmaceuticals Inc. CEO John Maraganore said in an interview.

Alnylam, which is developing experimental therapies targeting RNA interference, suffered a setback last year after a patient died in a phase 2 trial for its hemophilia therapy, fitusiran. The Right To Try Act allows patients to request for therapies that have cleared the phase 1 clinical trial stage.

"We strongly believe in bringing our medicines to patients when we have confidence around their efficacy and safety," Maraganore, who is also this year's BIO board chair, said.

The biotech's partner Sanofi is now leading fitusiran's development program, while Alnylam expects to launch patisiran, a medicine treating hereditary liver disorder, in the U.S. and Europe later this year.

There have never been any regulatory impediments for Alnylam to get experimental therapies to patients, Maraganore said — a sentiment echoed by several executives who spoke with S&P Global Market Intelligence at the annual event.

The U.S. Food and Drug Administration's compassionate-use program, also known as expanded access, was the traditional approach to get experimental medicines to desperate patients. Under the program, doctors made a case for their patients and demonstrated that they had exhausted all available options. The ultimate decision was taken by the FDA. In 2016, 99% of those requests were approved, according to an agency report.

"If you have a good doctor, a willing patient and a willing company, you can get a drug in the U.S. right now," said Brian Schwartz, chief medical officer and head of research and development for ArQule Inc., a biomarker-targeting biopharmaceutical company focused on oncology and certain rare diseases.

ArQule's miransertib AKT, an experimental medicine in early clinical trial for treating the extremely rare disease Proteus — also known as Elephant Man disease — easily falls into the new law's focus area.

A quarter of people with the disease — marked by unhindered cell growth resulting in overgrown bone and tissue, as well as cancers and thrombosis — will die before they are 18 years old, according to Schwartz.

Overall, the Massachusetts-based company receives about two compassionate-use requests a month for its pipeline therapies, Schwartz said — and the FDA has yet to deny one.

The 'heart and head' debate

Yet many Americans feel they are not getting the options.

As he signed the bill into law, Trump mentioned a man suffering from late-stage amyotrophic lateral sclerosis, or ALS — a neurodegenerative disorder also known as Lou Gehrig's disease.

The patient planned to travel to Israel for an experimental treatment called NurOwn — a stem cell therapy in late stage trials — being developed by Brainstorm Cell Therapeutics Inc.

Brainstorm President and CEO Chaim Lebovits attended the bill signing.

Now, the pressure is on, Lebovits said in an interview.

Brainstorm scheduled a call with ALS patients, physicians and advocates on June 7 to weigh options and develop a path forward.

"There are two sides of the debate about this with no simple answer," Lebovits said a day before the call, adding that broadly, companies were worried about fueling false hope.

"It's the heart against the head. I'm afraid I'm going to go with the heart, but I don't know," he said.

Breaking down business

Drugmakers are protected from liability for right-to-try patients, but not necessarily shielded from other fallouts if a drug does not work, or harms a patient.

Bioasis Technologies Inc. is a small, Connecticut-based company led by executives with big pharma background and looking to transport drugs through the blood-brain barrier with a preclinical technology.

The therapy's success would open a door for treating terminal tumors such as glioblastoma — the illness that Sen. John McCain, R-Ariz., has been diagnosed with — and late-stage cancers that had spread to other parts of the body and had few to no therapy options left.

But the company is not rushing it, executives said.

"Right To Try makes me nervous, because if the drugs are given improperly, not controlled, or given to the wrong patients … that can shut down an entire program," Caroline Hill, senior vice president of R&D operations, said. "So, the millions of people that it could have helped will never have it now."

Hill came to the company from oncology giant Bristol-Myers Squibb Co., along with Bioasis' president and CEO Mark Day.

"Big pharma does get a bad rap for not approving every compassionate-use request, but that's why [they don't approve them]," Hill said.

One potential advantage for Bioasis is that while its technology is new, its cargo across the blood-brain barrier is familiar: the company is running trials with versions of Roche Holding AG's Herceptin and Avastin — two blockbuster cancer therapies with extensive clinical data.

"With these being well-established products, it could be a good thing for us and patients," Day said.

In a fireside chat on the last day of BIO, FDA Commissioner Scot Gottlieb said that the agency was formulating a process for handling requests under the Right To Try Act.



5-Year Virtual Multichannel Revenue Forecast Underscores Segment's Opportunities

Highlights

The following post comes from Kagan, a research group within S&P Global Market Intelligence.

To learn more about our TMT (Technology, Media & Telecommunications) products and/or research, please request a demo.

Jul. 18 2018 — Driven by subscriber gains from AT&T Inc.'s DIRECTV NOW and DISH Network Corp.'s Sling TV and assisted by a batch of new arrivals in 2017 that includes Hulu LLC's Hulu with Live TV and Alphabet Inc.'s YouTube TV, Kagan estimates virtual multichannel services will reach nearly $2.82 billion in overall revenue in 2018, rising to more than $7.77 billion by 2022.

The large gains we project reflect the relative fledgling status of a market that is positioned to take advantage of widespread internet access by presenting new, alternative choices to traditional multichannel operators.

While the growth of virtual services is expected to dampen the projected decline in customers with some form of live linear channel package, we project the shift to have significant revenue implications for the market due to markedly lower average revenue per user rates associated with the new services.

Future developments could impair the segment over the five-year outlook. For instance, legacy distributors could revisit skinny bundles at competitive price points and leverage their existing customer relationships to undercut virtual providers.

Of note, traditional multichannel operators also providing wireline broadband have additional leverage with broadband bundles. For this category of ISPs, broadband could also be leveraged through the creation of prioritization lanes given the FCC's net neutrality reversal.

Recent M&A activity also clouds the future, led by the pursuit of key 21st Century Fox Inc. assets by Walt Disney Co. and Comcast Corp.

Disney has been quite transparent about the rationale behind the move. The media juggernaut plans to launch direct-to-consumer services leveraging its vast content libraries, including some of the world's most valuable franchises such as Marvel and Star Wars.

Although Comcast is playing its strategy cards closer to the vest, its pursuit of Sky PLC and 21st Century Fox, combined with the company's foray into wireless telecommunications, intimate wide-scale video-streaming plans.

FOX Could Reap Substantial Rewards For 2026 World Cup

Learn More

WatchTV's $15 Price Tag Outpaces Programming Costs Per Subscriber

Learn More

Listen: Wake Up Savers, Watch Out Banks - CDs Back In Vogue - Episode 25

Jul. 17 2018 — CD specials are back. More banks are offering the promotional rates on CDs, or certificates of deposits, to attract new customers. While that is good news for savers, it means funding costs likely will rise even more for banks. The episode shines a light on recent CD rates offered by banks and features commentary on smart deposit strategies from Bruce Hinkle of StoneCastle Cash Management and KeyCorp CFO Donald Kimble.

No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor's Financial Services LLC or its affiliates (collectively, S&P).


Listen: Financial Consumer Watchdog's Powerful Investigative Tool Faces Overhaul - Episode 26

Jul. 17 2018 — Mick Mulvaney, the acting director of the Consumer Financial Protection Bureau, has changed the way the agency operates and reduced enforcement actions against banks. Now, Mulvaney is turning his attention to a powerful tool used by the agency called the civil investigative demand. S&P Global Market Intelligence colleague Brian Cheung discusses how the CFPB uses the tool and what changes could mean for banks and consumers.

No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor's Financial Services LLC or its affiliates (collectively, S&P).


Watch: SNL Banker

Jul. 10 2018 — Transform internal data into vital insight with SNL Banker from S&P Global Market Intelligence. Our solution integrates seamlessly with internal systems to give U.S. community banks and credit unions greater visibility into finances and operations